216 related articles for article (PubMed ID: 32602273)
1. Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study.
Lee SH; Min KW; Lee BW; Jeong IK; Yoo SJ; Kwon HS; Choi YH; Yoon KH
Diabetes Metab J; 2021 May; 45(3):339-348. PubMed ID: 32602273
[TBL] [Abstract][Full Text] [Related]
2. Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Henry RR; Strange P; Zhou R; Pettus J; Shi L; Zhuplatov SB; Mansfield T; Klein D; Katz A
Diabetes Technol Ther; 2018 Nov; 20(11):715-724. PubMed ID: 30222367
[TBL] [Abstract][Full Text] [Related]
3. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
[TBL] [Abstract][Full Text] [Related]
4. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
[TBL] [Abstract][Full Text] [Related]
5. Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
Mathieu C; Dandona P; Phillip M; Oron T; Lind M; Hansen L; Thorén F; Xu J; Langkilde AM;
Diabetes Care; 2019 Jun; 42(6):1081-1087. PubMed ID: 30967434
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.
Araki E; Onishi Y; Asano M; Kim H; Ekholm E; Johnsson E; Yajima T
J Diabetes Investig; 2016 Jul; 7(4):555-64. PubMed ID: 27181422
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
[TBL] [Abstract][Full Text] [Related]
9. Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial.
Jiang LL; Zhang P; Liu BL; Yan RN; Ye L; Ma JH; Li FF
Biomed Res Int; 2021; 2021():6618257. PubMed ID: 34497852
[TBL] [Abstract][Full Text] [Related]
10. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
[TBL] [Abstract][Full Text] [Related]
12. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Bailey CJ; Gross JL; Hennicken D; Iqbal N; Mansfield TA; List JF
BMC Med; 2013 Feb; 11():43. PubMed ID: 23425012
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
Yang W; Ma J; Li Y; Li Y; Zhou Z; Kim JH; Zhao J; Ptaszynska A
J Diabetes; 2018 Jul; 10(7):589-599. PubMed ID: 29215189
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Mathieu C; Dandona P; Gillard P; Senior P; Hasslacher C; Araki E; Lind M; Bain SC; Jabbour S; Arya N; Hansen L; Thorén F; Langkilde AM;
Diabetes Care; 2018 Sep; 41(9):1938-1946. PubMed ID: 30026335
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
[TBL] [Abstract][Full Text] [Related]
17. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
Mudaliar S; Henry RR; Boden G; Smith S; Chalamandaris AG; Duchesne D; Iqbal N; List J
Diabetes Technol Ther; 2014 Mar; 16(3):137-44. PubMed ID: 24237386
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
Nauck MA; Del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
Diabetes Care; 2011 Sep; 34(9):2015-22. PubMed ID: 21816980
[TBL] [Abstract][Full Text] [Related]
19. Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study.
Kudo A; Machii N; Ono T; Saito H; Oshiro Y; Takahashi R; Oshiro K; Taneda Y; Higa M; Nakachi K; Yagi S; Masuzaki H; Sata M; Shimabukuro M
BMJ Open Diabetes Res Care; 2023 Apr; 11(2):. PubMed ID: 37028805
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Jabbour SA; Hardy E; Sugg J; Parikh S;
Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
